Journal of Biological Chemistry · 2011 · 83 citations · 29 references
Natural SciencesBiophysicsPharmacologyDrug DesignIon Channel BiophysicsStructural BiologyChannel StructureIon Channel PharmacologyIon Channel PhysiologyIon ChannelsPotassium Channel BiophysicsDrug Binding To Ion ChannelsIon Channel Drug BindingIon Channel StructureIon Channel Structure-function RelationshipsPotassium Channel PharmacologyRational DesignTwo-pore Domain Potassium ChannelsTwo-pore-domain Potassium Channels
Two-pore domain potassium (K(2P)) channels play a key role in setting the membrane potential of excitable cells. Despite their role as putative targets for drugs and general anesthetics, little is known about the structure and the drug binding site of K(2P) channels. We describe A1899 as a potent and highly selective blocker of the K(2P) channel TASK-1. As A1899 acts as an open-channel blocker and binds to residues forming the wall of the central cavity, the drug was used to further our understanding of the channel pore. Using alanine mutagenesis screens, we have identified residues in both pore loops, the M2 and M4 segments, and the halothane response element to form the drug binding site of TASK-1. Our experimental data were used to validate a K(2P) open-pore homology model of TASK-1, providing structural insights for future rational design of drugs targeting K(2P) channels.
29
Atomic structure of a voltage-dependent K+ channel in a lipid membrane-like environment
Stephen B. Long, Xiao Tao, Ernest B. Campbell et al. · Nature · 2007 · 1.4K citations
A structural basis for drug-induced long QT syndrome
John S. Mitcheson, Jun Chen, Monica Lin et al. · Proceedings of the National Academy of Sciences · 2000 · 937 citations
Medicine, Cardiology, Pharmacology +17
Crystal Structure of the Potassium Channel KirBac1.1 in the Closed State
Anling Kuo, Jacqueline M. Gulbis, Jennifer F. Antcliff et al. · Science · 2003 · 785 citations · Full text